Research Analysts’ Weekly Ratings Changes for Korro Bio (KRRO)

Several brokerages have updated their recommendations and price targets on shares of Korro Bio (NASDAQ: KRRO) in the last few weeks:

• 5/29/2026 – Korro Bio was upgraded by Lifesci Capital to “strong-buy”.
• 5/19/2026 – Korro Bio had its price target lowered by HC Wainwright from $20.00 to $15.00. They now have a “buy” rating on the stock.
• 5/18/2026 – Korro Bio is now covered by Citigroup Inc.. They set a “buy” rating and a $21.00 price target on the stock.
• 5/18/2026 – Korro Bio is now covered by Citigroup Inc.. They set a “buy” rating and a $21.00 price target on the stock.
• 5/9/2026 – Korro Bio was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/8/2026 – Korro Bio was upgraded by JonesTrading from “hold” to “strong-buy”.
• 4/8/2026 – Korro Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In related news, major shareholder Anthony A. Jr. Florence bought 207,100 shares of the company’s stock in a transaction dated Tuesday, March 10th. The stock was bought at an average price of $11.11 per share, with a total value of $2,300,881.00. Following the transaction, the insider owned 1,297,893 shares of the company’s stock, valued at approximately $14,419,591.23. This trade represents a 18.99% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Paul Edward Walker bought 207,100 shares of the company’s stock in a transaction dated Tuesday, March 10th. The stock was bought at an average cost of $11.11 per share, with a total value of $2,300,881.00. Following the transaction, the insider directly owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. The trade was a 18.99% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 1,657,320 shares of company stock worth $18,412,560. 4.80% of the stock is currently owned by insiders.

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.